Investing in stocks requires good decision making based on extensive study and professional review. If you are thinking about BIOCON stock, you are on the right track.
The organization also conducts research and development to provide cutting-edge solutions for complex medical conditions. This article will provide valuable information about BIOCON share price target from 2024 to 2030. Our review is largely based on the company's growth, performance, and future prospects, providing the information you need to make informed financing decisions.
Nestle India Share Price Target
About BIOCON Company
BIOCON Limited is a biopharmaceutical company based in Bangalore, India. Kiran Mazumdar-Shaw became its founder in 1978. About 120 countries, including the US and Europe, buy generic active pharmaceutical ingredients produced by the firm. Along with biosimilar insulins and antibodies sold under brand names in India, the company also makes innovative biologics. Many emerging markets also sell BIOCON's biosimilar medicines in formulation and bulk forms.
BIOCON Shares Current Performance And Market Indicators
Open Price: 385.00
Today's Low Price: 380.70
Today's High Price: 394.70
Current Price: 386.05
Market capitalization: 43,408 crore
P/E Ratio: 27.45
ROE: 5.17%
Dividend Yield: 0.14%
52-Week Low: 217.50
52-Week High: 394.70
Price Change Over the Past Year: +48.00% (+125.75 Increase)
Over the past year, BIOCON's share price has steadily increased by 48.00%, or 125.75, reaching an astonishing level. Currently, the stock is trading at 386.05, slightly higher than its opening price of 385.00. It has shown a significant upward trend today, ranging from a low of 380.70 to a high of 394.70, which also marks its 52-week high.
With a market capitalization of 43,408 crore, BIOCON is modestly valued at profits, as indicated by its P/E ratio of 27.45. The firm has a cautious return strategy, as can be seen from its low dividend yield of 0.14% and return on equity (ROE) of 5.17%. All things considered, BIOCON's share price performance shows significant growth momentum, especially over the past year.
BIOCON Shareholding
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Promoters
60.64%
60.64%
60.64%
60.64%
60.64%
Retail and Other
17.28%
17.31%
18.30%
20.05%
19.17%
Foreign Institutions
9.52%
7.96%
6.55%
5.63%
5.90%
Other Domestic Institutions
5.09%
5.83%
5.20%
5.11%
5.60%
Mutual Funds
7.47%
8.26%
9.31%
8.57%
8.69%
The BIOCON shareholding chart is referred to from the Groww website.
BIOCON Share Price Target 2024
In 2023, most Indian equities, including BIOCON, witnessed a spectacular rally. Despite the first months of consolidation, the market outlook is expected to remain optimistic in the first quarter of 2024. According to technical data, the minimum and maximum share price of BIOCON in 2024 is estimated to be 419.2 and 542.22, respectively.
BIOCON Share Price Target 2025
Based on current forecasts, Biocon Limited's share price is expected to reach Rs 553 by starting 2025. The share price can rise further with a target of Rs 620 by the end of 2025, provided that macroeconomic conditions, economic variables, and industry trends remain positive. This projected growth indicates that Biocon's performance is projected to improve.
BIOCON Share Price Target 2026
The initial price target for Biocon Limited in 2026 is 632, which indicates a positive trend. If the economic conditions remain good and the upward trend continues, the stock price may reach 711 by the end of 2026.
BIOCON Share Price Target 2027
Biocon share price performance in 2027 is generally consistent throughout the year. The share price is expected to be 725 at the start of the year. By mid-year, it is projected to fall slightly to 682, and by the end of the year, it is expected to fall marginally to 813. This shows a consistent performance with minor declines during the year, which means low volatility and a stable market forecast for Biocon shares in 2027.
BIOCON Share Price Target 2028
Biocon Share Price Target 2028 is expected to be 829 at the start, 779 in the middle, and 930 by the end.
BIOCON Share Price Target 2029
According to current market analysis and performance, the company's share price can reach 949 per share by the beginning of 2030. Which is an indication of the company's growth. Apart from this, the share price of BIOCON can reach 1064 per share by the end of 2029.
BIOCON Share Price Target 2030
If we look at the long term, the demand for the biopharma business is going to skyrocket, as according to the management, India will have the highest number of cancer patients, so the firm has devised several strategies to deal with it.
The firm exports its products to many major markets, including Europe, and as a result, the number of foreign investors in the company is decreasing.
If we look at the share price target of Biocon for 2030, then the first target is around 1085, while the second target is around 1217.
Jeyyam Global Foods Limited Ipo GMP Review And Details
Balance Sheet of BIOCON
Balance Sheet of Biocon (in Rs. Cr.) | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | |
EQUITIES AND LIABILITIES | |||||
SHAREHOLDER'S FUNDS | |||||
Equity Share Capital | 600.3 | 600.3 | 600.3 | 600 | 600 |
Total Share Capital | 600.3 | 600.3 | 600.3 | 600 | 600 |
Reserves and Surplus | 10,311.10 | 10,314.80 | 7,491.70 | 7,306.20 | 6,936.40 |
Total Reserves and Surplus | 10,312.00 | 10,315.70 | 7,492.60 | 7,307.10 | 6,937.30 |
Total Shareholders Funds | 10,912.30 | 10,916.00 | 8,092.90 | 7,907.10 | 7,537.30 |
NON-CURRENT LIABILITIES | |||||
Long Term Borrowings | 2,040.80 | 1,297.70 | 75.9 | 0 | 0.7 |
Deferred Tax Liabilities [Net] | 0 | 0 | 0 | 0 | 0 |
Other Long Term Liabilities | 95.6 | 92.8 | 83.7 | 90.1 | 23.4 |
Long Term Provisions | 28.3 | 25.4 | 25.6 | 26.3 | 21.4 |
Total Non-Current Liabilities | 2,164.70 | 1,415.90 | 185.2 | 116.4 | 45.5 |
CURRENT LIABILITIES | |||||
Short Term Borrowings | 0 | 0 | 0 | 0 | 0 |
Trade Payables | 447.6 | 485.9 | 380.9 | 372 | 521.2 |
Other Current Liabilities | 211.5 | 183.9 | 185.2 | 152.7 | 182.4 |
Short Term Provisions | 32.1 | 28.2 | 24.8 | 25.5 | 24.4 |
Total Current Liabilities | 691.2 | 698 | 590.9 | 550.2 | 728 |
Total Capital And Liabilities | 13,768.20 | 13,029.90 | 8,869.00 | 8,573.70 | 8,310.80 |
ASSETS | |||||
NON-CURRENT ASSETS | |||||
Tangible Assets | 885.4 | 882.7 | 784.3 | 708.2 | 698.6 |
Intangible Assets | 15 | 16.7 | 20.4 | 20.4 | 22.1 |
Capital Work-In-Progress | 545 | 328.9 | 270.3 | 164.6 | 151.9 |
Other Assets | 58 | 62 | 65.5 | 69.5 | 72.5 |
Fixed Assets | 1,518.00 | 1,304.90 | 1,155.10 | 977.3 | 945.1 |
Non-Current Investments | 9,255.60 | 8,949.80 | 5,017.80 | 5,073.40 | 4,814.00 |
Deferred Tax Assets [Net] | 7.4 | 22.8 | 120 | 146.4 | 179.5 |
Long Term Loans And Advances | 0 | 0 | 19 | 0 | 156.7 |
Other Non-Current Assets | 227.2 | 186.4 | 154.9 | 207.3 | 131.8 |
Total Non-Current Assets | 11,008.20 | 10,463.90 | 6,466.80 | 6,404.40 | 6,227.10 |
CURRENT ASSETS | |||||
Current Investments | 62.9 | 320.9 | 262.2 | 339.3 | 138.8 |
Inventories | 664.7 | 560.1 | 541.5 | 430.9 | 534.7 |
Trade Receivables | 1,048.10 | 658 | 700.6 | 588 | 573.2 |
Cash And Cash Equivalents | 585.7 | 720.3 | 689.3 | 601.2 | 375.3 |
Short Term Loans And Advances | 0 | 0 | 22.3 | 0 | 100.6 |
OtherCurrentAssets | 398.6 | 306.7 | 186.3 | 209.9 | 361.1 |
Total Current Assets | 2,760.00 | 2,566.00 | 2,402.20 | 2,169.30 | 2,083.70 |
Total Assets | 13,768.20 | 13,029.90 | 8,869.00 | 8,573.70 | 8,310.80 |
OTHER ADDITIONAL INFORMATION | |||||
CONTINGENT LIABILITIES, COMMITMENTS | |||||
Contingent Liabilities | 1,125.30 | 754.8 | 638.3 | 1,749.60 | 2,203.70 |
CIF VALUE OF IMPORTS | |||||
Raw Materials | 0 | 0 | 0 | 0 | 0 |
Stores, Spares And Loose Tools | 0 | 0 | 0 | 0 | 0 |
Trade/Other Goods | 0 | 0 | 0 | 0 | 0 |
Capital Goods | 0 | 0 | 0 | 0 | 0 |
EXPENDITURE IN FOREIGN EXCHANGE | |||||
Expenditure In Foreign Currency | 651 | 665.4 | 636 | 508.4 | 847.4 |
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | |||||
Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- |
EARNINGS IN FOREIGN EXCHANGE | |||||
FOB Value Of Goods | -- | -- | -- | -- | -- |
Other Earnings | 904.3 | 1,012.10 | 888.5 | 670.7 | 327.9 |
BONUS DETAILS | |||||
Bonus Equity Share Capital | 593.47 | 593.47 | 593.47 | 593.47 | 593.47 |
NON-CURRENT INVESTMENTS | |||||
Non-Current Investments Quoted Market Value | 15,475.60 | 13,096.50 | 16,871.80 | 15,346.80 | 6,798.30 |
Non-Current Investments Unquoted Book Value | 7,185.00 | 6,878.30 | 2,359.70 | 2,411.80 | 2,149.80 |
CURRENT INVESTMENTS | |||||
Current Investments Quoted Market Value | -- | -- | -- | -- | -- |
Current Investments Unquoted Book Value | 62.9 | 320.9 | 255 | 205 | 80 |
Balance Sheet of Biocon (in Rs. Cr.)
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
12 mths
12 mths
12 mths
12 mths
12 mths
EQUITIES AND LIABILITIES
SHAREHOLDER'S FUNDS
Equity Share Capital
600.3
600.3
600.3
600
600
Total Share Capital
600.3
600.3
600.3
600
600
Reserves and Surplus
10,311.10
10,314.80
7,491.70
7,306.20
6,936.40
Total Reserves and Surplus
10,312.00
10,315.70
7,492.60
7,307.10
6,937.30
Total Shareholders Funds
10,912.30
10,916.00
8,092.90
7,907.10
7,537.30
NON-CURRENT LIABILITIES
Long Term Borrowings
2,040.80
1,297.70
75.9
0
0.7
Deferred Tax Liabilities [Net]
0
0
0
0
0
Other Long Term Liabilities
95.6
92.8
83.7
90.1
23.4
Long Term Provisions
28.3
25.4
25.6
26.3
21.4
Total Non-Current Liabilities
2,164.70
1,415.90
185.2
116.4
45.5
CURRENT LIABILITIES
Short Term Borrowings
0
0
0
0
0
Trade Payables
447.6
485.9
380.9
372
521.2
Other Current Liabilities
211.5
183.9
185.2
152.7
182.4
Short Term Provisions
32.1
28.2
24.8
25.5
24.4
Total Current Liabilities
691.2
698
590.9
550.2
728
Total Capital And Liabilities
13,768.20
13,029.90
8,869.00
8,573.70
8,310.80
ASSETS
NON-CURRENT ASSETS
Tangible Assets
885.4
882.7
784.3
708.2
698.6
Intangible Assets
15
16.7
20.4
20.4
22.1
Capital Work-In-Progress
545
328.9
270.3
164.6
151.9
Other Assets
58
62
65.5
69.5
72.5
Fixed Assets
1,518.00
1,304.90
1,155.10
977.3
945.1
Non-Current Investments
9,255.60
8,949.80
5,017.80
5,073.40
4,814.00
Deferred Tax Assets [Net]
7.4
22.8
120
146.4
179.5
Long Term Loans And Advances
0
0
19
0
156.7
Other Non-Current Assets
227.2
186.4
154.9
207.3
131.8
Total Non-Current Assets
11,008.20
10,463.90
6,466.80
6,404.40
6,227.10
CURRENT ASSETS
Current Investments
62.9
320.9
262.2
339.3
138.8
Inventories
664.7
560.1
541.5
430.9
534.7
Trade Receivables
1,048.10
658
700.6
588
573.2
Cash And Cash Equivalents
585.7
720.3
689.3
601.2
375.3
Short Term Loans And Advances
0
0
22.3
0
100.6
OtherCurrentAssets
398.6
306.7
186.3
209.9
361.1
Total Current Assets
2,760.00
2,566.00
2,402.20
2,169.30
2,083.70
Total Assets
13,768.20
13,029.90
8,869.00
8,573.70
8,310.80
OTHER ADDITIONAL INFORMATION
CONTINGENT LIABILITIES, COMMITMENTS
Contingent Liabilities
1,125.30
754.8
638.3
1,749.60
2,203.70
CIF VALUE OF IMPORTS
Raw Materials
0
0
0
0
0
Stores, Spares And Loose Tools
0
0
0
0
0
Trade/Other Goods
0
0
0
0
0
Capital Goods
0
0
0
0
0
EXPENDITURE IN FOREIGN EXCHANGE
Expenditure In Foreign Currency
651
665.4
636
508.4
847.4
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS
Dividend Remittance In Foreign Currency
--
--
--
--
--
EARNINGS IN FOREIGN EXCHANGE
FOB Value Of Goods
--
--
--
--
--
Other Earnings
904.3
1,012.10
888.5
670.7
327.9
BONUS DETAILS
Bonus Equity Share Capital
593.47
593.47
593.47
593.47
593.47
NON-CURRENT INVESTMENTS
Non-Current Investments Quoted Market Value
15,475.60
13,096.50
16,871.80
15,346.80
6,798.30
Non-Current Investments Unquoted Book Value
7,185.00
6,878.30
2,359.70
2,411.80
2,149.80
CURRENT INVESTMENTS
Current Investments Quoted Market Value
--
--
--
--
--
Current Investments Unquoted Book Value
62.9
320.9
255
205
80
Balrampur Chini Share Price Target
Conclusion
Biocon's share price performance indicates a solid growth revolution, especially considering its massive 48.00% increase over the past year and current outlook at a 52-week high. Investors may find current price levels promising, as evidenced by good market indicators such as strong market capitalization and a decent P/E ratio of 27.45. While the return on equity and dividend yield are small, Biocon's consistent performance and significant price movement indicate the potential for future gains, making it an attractive option for investors looking for long-term growth. However, when setting future price objectives, investors should consider market conditions as well as business fundamentals.
FAQs
1. What is Biocon famous for?
Biocon is renowned for developing and commercializing the world's first Pichia-based rh-insulin in India. Biocon is the first business in the world to commercialize Insugen, a recombinant human insulin produced using a novel Pichia pastoris yeast production technology.
2. Is Biocon a good share to buy?
According to expert ratings, the long-term rating of Biocon Ltd. stock is "buy.".
3. What is the target of Biocon in 2025?
According to experts, the price target of Biocon is 333.29 INR, with a high estimate of 466.00 INR.
4. What is the future of Biocon?
Biocon's earnings and sales are expected to grow by 2.9% and 14.2%, respectively. EPS is estimated to grow by 5.7% annually. Return on equity is expected to be 6.5% after three years.
Disclaimer
This article is just for informational purposes. Forecasting of the share price targets is based on and referred to from various sources, media reports, and predictions done by brokerage houses from time to time.
We also state that we are not SEBI-registered financial advisors. So, kindly, before taking any kind of investment in the shares, please do counsel with the certified financial advisories.
If you have any corrections or find any wrong information, do let us know at our official [email protected]